XML 34 R24.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information (Tables)
6 Months Ended
Jun. 30, 2025
Segment Information  
Schedule of research and development costs

Three Months Ended

Three Months Ended

Six Months Ended

Six Months Ended

    

June 30, 2025

    

June 30, 2024

    

June 30, 2025

    

June 30, 2024

(In thousands)

Barzolvolimab/Anti-KIT Program

$

42,645

$

30,472

$

82,348

$

54,250

CDX-622

 

3,838

 

3,126

 

9,289

 

6,547

Other Programs (a)

 

7,713

 

6,089

 

15,173

 

10,551

Total R&D Expense

$

54,196

$

39,687

$

106,810

$

71,348

(a)Other program expenses primarily include research and development expenses related to early-stage programs, revenue-generating programs and discontinued programs.

Three Months Ended

Three Months Ended

Six Months Ended

Six Months Ended

    

June 30, 2025

    

June 30, 2024

    

June 30, 2025

    

June 30, 2024

 

(In thousands)

Personnel

$

14,129

$

11,881

$

27,729

$

23,321

Laboratory supplies

 

1,544

 

1,615

 

3,712

 

2,923

Facility

 

1,398

 

1,250

 

2,803

 

2,536

Product development (b)

 

33,536

 

22,667

 

65,702

 

38,192

Other expenses (c)

 

3,589

 

2,274

 

6,864

 

4,376

Total R&D expense

$

54,196

$

39,687

$

106,810

$

71,348

(b)

Product development expenses include clinical investigator site fees, external trial monitoring costs, data accumulation costs, contracted research and outside clinical drug product manufacturing.

(c)

Other expenses primarily include research and development consulting, insurance, licensing and software expenses.